Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Minocycline hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Acnamino MR 100mg Capsules (referred to as Acnamino MR throughout this leaflet) contain the active ingredient minocycline. Minocycline is a tetracycline antibiotic used in the treatment of acne. It is thought that acne is partly due to, or made worse by, infection with a type of bacteria called Propionibacterium Acnes. Treating acne with Acnamino MR is intended to reduce the infection with this bacterium and so help in the overall treatment of acne
e Acnamino MR Do not take Acnamino MR:
precautions needed to avoid pregnancy
Acnamino MR Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Dosage and frequency of administration
swallowing, tightness in your throat or chest, wheezing, coughing or noisy breathing, feeling faint, dizzy or fainting. You may also develop a rash that's swollen, raised or itchy. These are symptoms of a life threatening allergic reaction (anaphylaxis/ anaphylactoid reaction) (rare)
the hands and feet
you can help provide more information on the safety of this medicine.
Acnamino MR Store the capsules in the original package. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the outer carton and on each blister strip after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Acnamino MR contains The active substance is minocycline. Each capsule contains 100 mg of the active substance minocycline as minocycline hydrochloride. The other ingredients are: microcrystalline cellulose, povidone, croscarmelose sodium, magnesium stearate, iron oxide red (E-172), silica colloidal anhydrous, iron oxide yellow (E-172), hypromellose phthalate, triethyl citrate, opadry OY-S-24932 pink (which contains hypromellose 2910, macrogol 6000, titanium dioxide (E-171), talc, iron oxide red (E-172)), carnauba wax, hard Gelatin Capsule (which contains gelatin, titanium dioxide (E-171), yellow iron oxide (E-172), black iron oxide (E-172), red iron oxide (E-172)). What Acnamino MR looks like and content of the pack Acnamino MR is a hard gelatin capsule, with an opaque-buff body and an opaque-brown cap, containing one pink filmcoated tablet, and one peach enteric-coated tablet. These MR capsules are intended to provide "modified r elease" of the active substance minocycline so that some is released in the stomach and some in the small intestine. Acnamino MR is available in packs of 56 capsules, in foil blister strips. Marketing Authorization Holder and Manufacturer Dexcel®-Pharma Ltd., 2nd Floor, Bourn, 1 Manor House Drive, Coventry, CV1 2FX, UK This leaflet was last revised in January 2026.
Acnamino MR 100mg Capsules comes as capsule containing 100mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Acnamino MR 100mg Capsules is minocycline hydrochloride.
Medicines with the same active substance, strength and form include: Minocin MR 100 mg Modified Release Capsules. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Acnamino MR 100mg Capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Acnamino MR 100 mg capsules are indicated for the treatment of acne.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Posology
Adults
One 100 mg capsule every 24 hours
Paediatric Population
Children over 12 years:
One 100 mg capsule every 24 hours
Children under 12 years:
Minocycline should not be used in children under 12 years of age
Elderly:
Dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Renal insufficiency:
Minocycline must not be given to persons in renal failure. In lesser degrees of renal insufficiency, reduction of dosage and monitoring of renal function may be required (see sections 4.3 and 4.4).
Hepatic insufficiency:
Minocycline should be used with caution in patients with hepatic dysfunction (see section 4.4).
Treatment of acne should be continued for a minimum of 6 weeks, and where possible limited to a maximum of six months. If, after six months, there is no satisfactory response, Acnamino MR should be discontinued and other therapies considered.
If Acnamino MR is to be continued for longer than six months, patients should be monitored (including laboratory investigations) at least three monthly thereafter for signs and symptoms of hepatitis or systemic lupus erythematosus (SLE) or unusual pigmentation (see section 4.4 Special Warnings and Precautions).
Method of Administration
To reduce the risk of oesophageal irritation and ulceration, the capsules should be swallowed whole with plenty of fluid, while sitting or standing. Unlike other tetraacyclines, absorption of minocycline is not significantly impaired by food or moderate amounts of milk.
Use of minocycline is contraindicated in the following:
• Hypersensitivity to the active substance minocycline, other tetracyclines or to any of the excipients listed in section 6.1.
• Pregnancy and lactation.
• Children under the age of 12 years.
• Complete renal failure.
Rare, anaphylaxis/anaphylactoid reactions including shock and fatalities have been associated with the administration of minocycline (see section 4.8 Undesirable effects).
Acnamino MR should be used with caution in patients with hepatic dysfunction and in conjunction with alcohol and other hepatotoxic drugs. It is recommended that alcohol consumption should remain within the Government's recommended limits.
Rare cases of auto-immune hepatotoxicity and isolated cases of systemic lupus erythematosus (SLE) and also exacerbation of pre-existing SLE have been reported. If patients develop signs or symptoms of SLE or hepatotoxicity, or suffer exacerbation of pre-existing SLE, minocycline should be discontinued.
Other rare, serious events have occurred with minocycline including Stevens-Johnson Syndrome and toxic epidermal necrolysis (see section 4.8 Undesirable effects). Acnamino MR should be discontinued if either of these serious skin reactions is suspected.
Minocycline is contraindicated in persons with renal failure. Clinical studies have shown that there is no significant drug accumulation in patients with renal impairment when they are treated with minocycline in the recommended doses. In cases of severe renal insufficiency, reduction of dosage and monitoring of renal function may be required. The anti-anabolic action of the tetracyclines may cause an increase in serum urea. In patients with significantly impaired renal function, higher serum levels of tetracyclines may lead to uraemia, hyperphosphataemia and acidosis. If renal impairment exists, even usual oral and parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity.
Caution is advised in patients with myasthenia gravis as tetracyclines can cause weak neuromuscular blockade.
Cross-hypersensitivity between tetracyclines may occur in patients (see section 4.3).
Cross-resistance between tetracyclines may develop in micro-organisms and cross-sensitisation in patients. Acnamino MR should be discontinued if there are signs/symptoms of overgrowth of resistant organisms, e.g. enteritis, glossitis, stomatitis, vaginitis, pruritus and or Staphylococcal enteritis.
Patients taking oral contraceptives should be warned that if diarrhoea or breakthrough bleeding occur there is a possibility of contraceptive failure.
Minocycline may cause hyperpigmentation at various body sites (see Administration and section 4.8 Undesirable Effects). Hyperpigmentation may present regardless of dose or duration of therapy but develops more commonly during long term treatment. Patients should be advised to report any unusual pigmentation without delay and Acnamino MR should be discontinued.
If a photosensitivity reaction occurs, patients should be warned to avoid direct exposure to natural or artificial light and to discontinue therapy at the first signs of skin discomfort.
As with other tetracyclines, bulging fontanelles in infants and benign intracranial hypertension in juveniles and adults have been reported. Presenting features were headache and visual disturbances including blurring of vision, scotoma and diplopia. Permanent vision loss has been reported.
Treatment should cease if evidence of raised intracranial pressure develops.
Elderly:
Dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Paediatric population:
Acnamino MR is contraindicated in children of less than 12 years of age. The use of tetracyclines during tooth development in children under the age of 12 years may cause permanent discolouration. Enamel hypoplasia has also been reported.
Laboratory monitoring:
Periodic laboratory evaluations of organ system function, including haematopoietic, renal and hepatic should be conducted.
Excipient information:
Sodium
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 'sodium-free'.
Tetracyclines depress plasma prothrombin activity and reduced doses of concomitant anticoagulants may be necessary.
Diuretics may aggravate nephrotoxicity by volume depletion.
Minocycline should not be used with beta-lactam antibacterial agents due to the possibility of antagonism.
Bacteriostatic drugs may interfere with the bactericidal action of penicillin. Avoid giving tetracycline-class drugs in conjunction with penicillin. Absorption of minocycline is impaired by the concomitant administration of antacids, iron, calcium, magnesium, aluminium, bismuth and zinc salts (interactions with specific salts, antacids, bismuth containing ulcer – healing drugs, quinapril which contains a magnesium carbonate excipient). It is recommended that any indigestion remedies, vitamins, or other supplements containing these salts are taken at least 3 hours before or after a dose of Acnamino MR. Unlike earlier tetracyclines, absorption of minocycline is not significantly impaired by food or moderate amounts of milk.
The concomitant use of tetracyclines may reduce the efficacy of oral contraceptives.
Administration of isotretinoin should be avoided shortly before, during and shortly after Acnamino MR therapy. Each drug alone has been associated with pseudotumor cerebri (benign intracranial hypertension) (see section 4.4 Special Warngings and Precautions).
Interference with laboratory and other diagnostic tests:
False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.
Pregnancy
Minocycline is contraindicated during pregnancy as it can cause fetal harm (see section 4.3).
Results of animal studies indicate that tetracyclines cross the placenta, are found in foetal tissues and can have toxic effects on the developing foetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. Acnamino MR therefore, should not be used in pregnancy unless considered essential.
In humans, minocycline like other tetracycline-class antibiotics, crosses the placenta and may cause foetal harm when administered to a pregnant woman. In addition, there have been post marketing reports of congenital abnormalities including limb reduction. If Acnamino MR is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to the foetus.
The use of drugs of the tetracycline class during tooth development (last half of pregnancy) may cause permanent discolouration of the teeth (yellow-grey-brown). This adverse reaction is more common during long term use of the drugs but has been observed following repeated short term courses. Enamel hypoplasia has also been reported.
Tetracyclines administered during the last trimester form a stable calcium complex throughout the human skeleton. A decrease in fibula growth rate has been observed in premature human infants given oral tetracyclines in doses up to 25mg/kg every 6 hours. Changes in fibula growth rate were shown to be reversible when the drug was discontinued.
Breast-feeding
Minocycline is contraindicated during breast-feeding (see section 4.3).
Tetracyclines have been found in the milk of lactating women who are taking a drug in this class. Permanent tooth discolouration may occur in the developing infant and enamel hypoplasia has been reported.
Headache, light-headedness, dizziness, tinnitus and vertigo (more common in women) and, rarely, impaired hearing have occurred with minocycline. Patients should be warned about the possible hazards of driving or operating machinery during treatment. These symptoms may disappear during therapy and usually disappear when the drug is discontinued.
The assessment of side effects is based on the following frequency information:
Common: (≥1/100 to <1/10)
Uncommon: (≥1/1 000 to <1/100)
Rare: (≥1/10 000 to <1/1 000)
Very Rare: (<1/10 000)
Not known (cannot be estimated from the available data).
System Organ Class
Frequency
Adverse Reaction
Infections and Infestations
Very Rare
Oral and anogenital candidiasis, vulvovaginitis
Blood and Lymphatic System Disorders
Rare
Eosinophilia, leucopoenia, neutropenia, thrombocytopenia
Very Rare
Haemolytic anaemia, pancytopenia
Not known
Agranulocytosis
Immune System Disorders
Rare
Anaphylaxis/anaphylactoid reaction (including shock and fatalities)
Not known
Hypersensitivity, pulmonary infiltrates, anaphylactoid purpura, Polyarteritis nodosa
Endocrine Disorders
Very Rare
Abnormal thyroid function, brown-black discolouration of the thyroid
Metabolism and Nutrition Disorders
Rare
Anorexia
Nervous System Disorders
Common
Dizziness (light-headedness)
Rare
Headache, hypaesthesia, paraesthesia, intracranial hypertension, vertigo
Very Rare
Bulging fontanelle
Not Known
Convulsions, sedation
Ear and Labyrinth Disorders
Rare
Impaired hearing, tinnitus
Cardiac Disorders
Rare
Myocarditis, pericarditis
Respiratory, Thoracic and Mediastinal Disorders
Rare
Cough, dyspnoea
Very Rare
Bronchospasm, exacerbation of asthma, pulmonary eosinophilia
Not Known
Pneumonitis
Gastrointestinal Disorders
Rare
Diarrhoea, nausea, stomatitis, discolouration of teeth (including adult tooth discolouration), vomiting
Very Rare
Dyspepsia, dysphagia, enamel hypoplasis, enterocolitis, oesophagitis, oesophageal ulceration, glossitis, pancreatitis, pseudomembranous colitis
Not Known
Oral cavity discolouration (including tongue, lip and gum)
Hepatobiliary Disorders
Rare
Increased liver enzymes, hepatitis, autoimmune toxicity
Very Rare
Hepatic cholestatis, hepatic failure (including fatalities), hyperbilirubinaemia, jaundice
Not Known
Autoimmune hepatitis
Skin and Subcutaneous Tissue Disorders
Rare
Alopecia, erythema multiforme, erythema nodosum, fixed drug eruption, hyperpigmentation of skin, photosensitivity, pruritus, rash, urticaria
Very Rare
Angioedema, exfoliative dermatitis, hyperpigmentation of nails, Stevens-Johnson Syndrome, toxic epidermal necrolysis, vasculitis
Musculoskeletal, Connective Tissue Disorders
Rare
Arthralgia, lupus-like syndrome, myalgia
Very Rare
Arthritis, bone discolouration, cases of or exacerbation of systemic lupus erythematosus (SLE), joint stiffness, joint swelling
Renal and Urinary Disorders
Rare
Increase serum urea, acute renal failure, interstitial nephritis
Reproductive System and Breast Disorders
Very Rare
Balanitis
General Disorders and Administration Site Conditions
Uncommon
Fever
Very Rare
Discolouration of secretions
The following syndromes have been reported. In some cases involving these syndromes, death has been reported. As with other serious adverse reactions, if any of these syndromes are recognised, the drug should be discontinued immediately:
• Hypersensitivity syndrome consisting of cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, pericarditis.
• Fever and lymphadenopathy may be present.
• Lupus-like syndrome consisting of positive antinuclear antibody, arthralgia, arthritis, joint stiffness or joint swelling, and one or more of the following: fever, myalgia, hepatitis, rash, vasculitis.
• Serum sickness-like syndrome consisting fever, urticaria or rash, and arthralgia, arthritis, joint stiffness or joint swelling. Eosinophilia may be present.
• Hyperpigmentation of various body sites including the skin, nails, teeth, oral mucosa, bones, thyroid, eyes (including sclera and conjunctiva), breast milk, lacrimal secretions and perspiration has been reported.
This blue/black/grey or muddy-brown discolouration may be localised or diffuse. The most frequently reported site is in the skin. Pigmentation is often reversible on discontinuation of the drug, although it may take several months or may persist in some cases. The generalised muddy-brown skin pigmentation may persist, particularly in areas exposed to the sun.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Dizziness, nausea and vomiting are the adverse effects most commonly seen with overdose. There is no specific antidote. In cases of overdose, discontinue medication, treat symptomatically with gastric lavage and appropriate supportive measures. Minocycline is not removed in significant quantities by haemodialysis or peritoneal dialysis.
Ask anything about Acnamino MR 100mg Capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.